Skip to content
Stack & save: 10% off 3+ vials, 15% off 5+ · Free shipping over $250
Cart 0
Compound Files

Follistatin Research Guide: Activin, Myostatin, and the Form Question

Follistatin is more than a myostatin keyword. Its research includes activin binding and distinct protein forms, making the exact construct essential to interpreting a sample or a study.

Hero Peptides Research TeamUpdated Nov 20265 min read

Quick facts

Catalog name Follistatin
Molecule class Protein; the supplied form requires confirmation
Research themes Activin binding, myostatin-related signaling, and form-dependent localization
Hero catalog size 1 mg
Product form Isoform/construct, sequence, and expression details unconfirmed in the supplied export
Hero product Follistatin

Follistatin is a protein studied for interactions with activin and other signaling ligands, including myostatin. Its research history extends well beyond the muscle-growth summaries that often dominate search results.

Hero’s supplied catalog lists Follistatin in a 1 mg format without identifying the isoform, construct, or sequence. That gap matters: follistatin-related numbers can refer to precursor or mature forms, and they should not be treated as interchangeable labels.

Origin story: an activin-related research protein

Ueno and colleagues reported isolation and partial characterization of follistatin in 1987. Their work described a protein associated with suppression of follicle-stimulating hormone release in the tested system. This historical activity is part of the molecule’s identity, not evidence that every modern preparation is the same (Ueno et al., 1987).

Subsequent research examined the human precursor and genomic organization. Shimasaki and colleagues reported sequences encoding 344- and 317-residue precursors arising through alternative splicing. Those precursor descriptions should not be confused with the mature-form numbers used elsewhere (Shimasaki et al., 1988).

A product called Follistatin therefore needs a specific material description. The name alone does not establish which sequence, expression system, processing state, or additional construct features are present. Scientific comparisons start with that identification.

How follistatin form changes the research question

Sugino and colleagues investigated molecular heterogeneity of follistatin, including forms with 315- and 288-residue cores and differences in heparan-sulfate-related binding. Their work helps explain why form can affect how a protein interacts with its biological environment (Sugino et al., 1993).

This is more specific than saying one form is universally better. Binding to a surface-associated component, interacting with a ligand, and producing a downstream response are different properties. Which one matters depends on the experiment.

For a laboratory comparison, record the actual sequence or construct and the functional assay used to characterize it. A vial quantity cannot distinguish a mature protein from a precursor-related label or an engineered preparation. The relevant specification must do that work.

What the follistatin studies actually tested

The literature includes protein characterization, gene and precursor studies, form-dependent interactions, and animal experiments. These contributions should be compared by their actual question.

Study Setting Contribution Boundary
Ueno et al., 1987 Isolation and protein characterization Helped define follistatin as a research protein Does not characterize a current catalog sample
Shimasaki et al., 1988 Human precursor and genomic work Identified alternatively spliced precursor sequences Precursor numbering differs from mature-form terminology
Sugino et al., 1993 Protein-form and binding experiments Examined molecular heterogeneity and surface-related binding Form-specific results should not be generalized to an unspecified construct
Lee and McPherron, 2001 Ligand-binding and transgenic mouse work Investigated myostatin regulation and muscle responses Genetic expression is different from exposure to a research vial

Lee and McPherron examined myostatin interactions and generated transgenic mice expressing high levels of relevant proteins, including follistatin, using a muscle-specific promoter. Their work supports a mechanistic research connection between ligand regulation and muscle biology (Lee and McPherron, 2001).

It does not establish that a nominal 1 mg preparation reproduces the same biological exposure. A genetic-expression experiment and an externally supplied protein are different interventions.

Why the myostatin shortcut misses important details

Describing follistatin only as a myostatin blocker leaves out its broader ligand-binding research and form-dependent behavior. A useful claim names the actual ligand, test system, and endpoint. It should not imply that every downstream pathway remains unaffected.

The cited studies also do not establish improved human strength or body composition from Hero’s catalog material. That conclusion would require direct evidence for the actual product and outcome, rather than inference from transgenic mice or a binding experiment.

Follistatin should not be confused with an upstream GH secretagogue or an IGF-I analog. Those are different molecules and research pathways. A shared interest in tissue growth does not establish equivalent structures, mechanisms, or experimental uses.

Even within the follistatin literature, compare like with like. An assay using a specified mature form cannot automatically define the activity of a different construct. The material description is part of the result, not a footnote.

Laboratory planning for Hero’s 1 mg entry

Confirm the exact form before adopting a paper’s method. The key documentation includes sequence or construct, processing state, expression details, and the stated quantity basis. Additional tags or modifications, if present, should be identified rather than assumed absent.

Choose analytical and functional checks appropriate to the intended experiment. Protein identity, integrity, and ligand-binding activity answer different questions. A single purity percentage does not establish all three or prove equivalence between two preparations.

For biological work, document the ligand, cell model, matrix conditions, and comparator. Decide whether the experiment tests binding, signaling, proliferation, or another endpoint. A downstream change should not automatically be assigned to one ligand without a design that can support that attribution.

Follow preparation and storage conditions documented for the actual protein. A 1 mg label is not a concentration or stability specification. Retain lot and handling history alongside the results so differences between experiments can be investigated.

Follistatin research FAQ

Does Hero’s export identify a specific form?

No. It lists Follistatin and 1 mg without specifying the isoform or construct. The guide leaves that identity unconfirmed.

Are precursor and mature-form numbers interchangeable?

No. They can describe different sequence states. Check the actual construct rather than equating a number in one paper with a different form in another.

Is follistatin research limited to myostatin?

No. Activin binding and form-dependent interactions are important parts of the research history. A mechanism claim should identify the tested ligand.

Does transgenic mouse research validate a protein vial?

No. Genetic expression and exposure to an external preparation are different interventions. Each requires evidence for its actual material and conditions.

Follistatin. View catalog product

References

  1. Ueno N, et al. Isolation and partial characterization of follistatin: a single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone. Proc Natl Acad Sci USA 1987;84:8282-8286. Source.
  2. Shimasaki S, et al. Primary structure of the human follistatin precursor and its genomic organization. Proc Natl Acad Sci USA 1988;85:4218-4222. Source.
  3. Sugino K, et al. Molecular heterogeneity of follistatin, an activin-binding protein. Higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell. J Biol Chem. 1993;268:15579-15587. Source.
  4. Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 2001;98:9306-9311. Source.
For laboratory research use only. Not for human or veterinary use. This article is educational and is not medical advice.

Read next

Add 3 vials for 10% off
Build my stack